|
Jul 22
|
SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients
|
|
Jul 16
|
SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry
|
|
Jul 10
|
SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jul 2
|
SeaStar Medical Announces Positive Nasdaq Listing Determination
|
|
Jun 25
|
Top Midday Gainers
|
|
Jun 25
|
SeaStar Medical Reports Update on Nasdaq Listing Status
|
|
Jun 24
|
SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
|
|
Jun 20
|
SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
|
|
May 28
|
SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
|
|
Oct 9
|
SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit
|
|
Oct 8
|
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
|
|
Sep 25
|
SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial
|
|
Jul 26
|
Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s
|
|
Jul 23
|
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device
|
|
Jun 12
|
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
|
|
Jun 11
|
SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
|
|
Jun 11
|
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
|
|
May 24
|
Seastar touts positive case studies for selective cytopheretic device
|
|
May 22
|
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility
|
|
Mar 12
|
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
|